HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. LRCX
7. LVS
8. CSX
9. QGEN
10. KNX

Go back to HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS

Halozyme Therapeutics (HALO) Tops Q4 EPS by 18c; Guides FY23

February 21, 2023 4:04 PM EST

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181 million versus the consensus estimate of $192.05 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 revenue of $815-845 million, versus the consensus of... More